Al-Razi Medical Valuation
Is 9572 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 9572 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 9572 (SAR52.8) is trading above our estimate of fair value (SAR4.39)
Significantly Below Fair Value: 9572 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 9572?
Other financial metrics that can be useful for relative valuation.
| What is 9572's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | ر.س80.26m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.5x |
| Enterprise Value/EBITDA | 21.3x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 9572's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 28.3x | ||
9574 Professional Medical Expertise | 13.7x | n/a | ر.س315.0m |
9530 Arabian International Healthcare Holding | 35.6x | n/a | ر.س843.1m |
2230 Saudi Chemical Holding | 37.1x | n/a | ر.س6.8b |
9587 Lana Medical | 26.8x | n/a | ر.س147.4m |
9572 Al-Razi Medical | 39.3x | n/a | ر.س80.3m |
Price-To-Earnings vs Peers: 9572 is expensive based on its Price-To-Earnings Ratio (39.3x) compared to the peer average (28.3x).
Price to Earnings Ratio vs Industry
How does 9572's PE Ratio compare vs other companies in the Asian Healthcare Industry?
Price-To-Earnings vs Industry: 9572 is expensive based on its Price-To-Earnings Ratio (39.3x) compared to the Asian Healthcare industry average (21.8x).
Price to Earnings Ratio vs Fair Ratio
What is 9572's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 39.3x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 9572's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.